share_log

HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. Maintains Buy on Gain Therapeutics, Lowers Price Target to $9

HC Wainwright & Co.維持增益療法的買入,將目標價下調至9美元
Benzinga ·  2023/12/04 06:47

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $10 to $9.

HC Wainwright & Co. 分析師Raghuram Selvaraju維持Gain Therapeutics(納斯達克股票代碼:GANX)的買入,並將目標股價從10美元下調至9美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論